22 results on '"Luostarinen T"'
Search Results
2. Circulating free testosterone and risk of aggressive prostate cancer: Prospective and Mendelian randomisation analyses in international consortia.
- Author
-
Watts EL, Perez-Cornago A, Fensom GK, Smith-Byrne K, Noor U, Andrews CD, Gunter MJ, Holmes MV, Martin RM, Tsilidis KK, Albanes D, Barricarte A, Bueno-de-Mesquita B, Chen C, Cohn BA, Dimou NL, Ferrucci L, Flicker L, Freedman ND, Giles GG, Giovannucci EL, Goodman GE, Haiman CA, Hankey GJ, Huang J, Huang WY, Hurwitz LM, Kaaks R, Knekt P, Kubo T, Langseth H, Laughlin G, Le Marchand L, Luostarinen T, MacInnis RJ, Mäenpää HO, Männistö S, Metter EJ, Mikami K, Mucci LA, Olsen AW, Ozasa K, Palli D, Penney KL, Platz EA, Rissanen H, Sawada N, Schenk JM, Stattin P, Tamakoshi A, Thysell E, Tsai CJ, Tsugane S, Vatten L, Weiderpass E, Weinstein SJ, Wilkens LR, Yeap BB, Allen NE, Key TJ, and Travis RC
- Subjects
- Biomarkers, Humans, Male, Mendelian Randomization Analysis, Prostate, Risk Factors, Testosterone, Prostatic Neoplasms epidemiology, Prostatic Neoplasms genetics, Sex Hormone-Binding Globulin analysis
- Abstract
Previous studies had limited power to assess the associations of testosterone with aggressive disease as a primary endpoint. Further, the association of genetically predicted testosterone with aggressive disease is not known. We investigated the associations of calculated free and measured total testosterone and sex hormone-binding globulin (SHBG) with aggressive, overall and early-onset prostate cancer. In blood-based analyses, odds ratios (OR) and 95% confidence intervals (CI) for prostate cancer were estimated using conditional logistic regression from prospective analysis of biomarker concentrations in the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group (up to 25 studies, 14 944 cases and 36 752 controls, including 1870 aggressive prostate cancers). In Mendelian randomisation (MR) analyses, using instruments identified using UK Biobank (up to 194 453 men) and outcome data from PRACTICAL (up to 79 148 cases and 61 106 controls, including 15 167 aggressive cancers), ORs were estimated using the inverse-variance weighted method. Free testosterone was associated with aggressive disease in MR analyses (OR per 1 SD = 1.23, 95% CI = 1.08-1.40). In blood-based analyses there was no association with aggressive disease overall, but there was heterogeneity by age at blood collection (OR for men aged <60 years 1.14, CI = 1.02-1.28; P
het = .0003: inverse association for older ages). Associations for free testosterone were positive for overall prostate cancer (MR: 1.20, 1.08-1.34; blood-based: 1.03, 1.01-1.05) and early-onset prostate cancer (MR: 1.37, 1.09-1.73; blood-based: 1.08, 0.98-1.19). SHBG and total testosterone were inversely associated with overall prostate cancer in blood-based analyses, with null associations in MR analysis. Our results support free testosterone, rather than total testosterone, in the development of prostate cancer, including aggressive subgroups., (© 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.)- Published
- 2022
- Full Text
- View/download PDF
3. Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV).
- Author
-
Gray P, Luostarinen T, Vänskä S, Eriksson T, Lagheden C, Man I, Palmroth J, Pimenoff VN, Söderlund-Strand A, Dillner J, and Lehtinen M
- Subjects
- Adolescent, Adult, Female, Finland epidemiology, Human papillomavirus 18 isolation & purification, Humans, Male, Papillomavirus Infections prevention & control, Papillomavirus Vaccines administration & dosage, Seroepidemiologic Studies, Sex Factors, Unsafe Sex, Young Adult, Human papillomavirus 16 immunology, Human papillomavirus 18 immunology, Papillomavirus Infections epidemiology, Papillomavirus Infections virology, Papillomavirus Vaccines immunology, Risk-Taking, Sexual Behavior statistics & numerical data
- Abstract
Oncogenic non-vaccine human papillomavirus (HPV) types may conceivably fill the vacated ecological niche of the vaccine types. The likelihood of this may differ by the risk of acquiring HPV infections. We examined occurrence of HPV types among vaccinated and unvaccinated subgroups of 1992-1994 birth cohorts with differing acquisition risks up to 9 years post-implementation of HPV vaccination in 33 Finnish communities randomized to: Arm A (gender-neutral HPV16/18 vaccination), Arm B (girls-only HPV16/18 vaccination and hepatitis B-virus (HBV) vaccination of boys), and Arm C (gender-neutral HBV vaccination). Out of 1992-1994 born resident boys (31,117) and girls (30,139), 8,618 boys and 15,615 girls were vaccinated, respectively, with 20-30% and 50% coverage in 2007-2009. In 2010-2013, 8,868 HPV16/18 and non-HPV vaccinated females, and in 2014-2016, 5,574 originally or later (2010-2013) HPV16/18 vaccinated females attended two cervical sampling visits, aged 18.5 and 22-years. The samples were typed for HPV6/11/16/18/31/33/35/39/45/51/52/56/58/59/66/68 using PCR followed by MALDI-TOF MS. HPV prevalence ratios (PR) between Arms A/B vs. C were calculated for Chlamydia trachomatis positives (core-group), and negatives (general population minus core group). At both visits the vaccine-protected HPV type PRs did not significantly differ between the core-group and non-core group. Among the vaccinated 18-year-olds, HPV51 occurrence was overall somewhat increased (PR
core = 1.4, PRnon-core. = 1.4) whereas the HPV52 occurrence was increased in the core-group only (PRcore = 2.5, PRnon-core = 0.8). Among the non-HPV vaccinated 18-year-olds, the HPV51/52 PRs were higher in the core-group (PRcore = 3.8/1.8, PRnon-core = 1.2/1.1). The 22-year-olds yielded no corresponding observations. Monitoring of the sexual risk-taking core-group may detect early tendencies for HPV type replacement., (© 2019 UICC.)- Published
- 2019
- Full Text
- View/download PDF
4. Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III).
- Author
-
Lehtinen M, Luostarinen T, Vänskä S, Söderlund-Strand A, Eriksson T, Natunen K, Apter D, Baussano I, Harjula K, Hokkanen M, Kuortti M, Palmroth J, Petäjä T, Pukkala E, Rekonen S, Siitari-Mattila M, Surcel HM, Tuomivaara L, Paavonen J, Nieminen P, Dillner J, Dubin G, and Garnett G
- Subjects
- Adolescent, Child, Cohort Studies, Female, Finland epidemiology, Follow-Up Studies, Humans, Male, Papillomavirus Infections epidemiology, Papillomavirus Infections immunology, Prognosis, Sex Factors, Immunity, Herd immunology, Papillomaviridae classification, Papillomaviridae immunology, Papillomavirus Infections prevention & control, Papillomavirus Vaccines therapeutic use
- Abstract
With optimal strategy, human papillomavirus (HPV) vaccines have the potential to control HPV. We have assessed vaccine efficacy (VE), herd effect (HE) of HPV vaccination and overall protective effectiveness (PE) against high-risk HPV infections by HPV type and vaccination strategy in a community-randomized trial using the bivalent HPV16/18 vaccine. We randomized 33 communities to gender-neutral HPV vaccination (Arm A), HPV vaccination of girls and hepatitis B-virus (HBV) vaccination of boys (Arm B) and gender-neutral HBV vaccination (Arm C). Entire 1992-1995 male (40,852) and female (39,420) birth cohorts were invited, and 11,662 males and 20,513 females vaccinated with 20-30% and 45% coverage in 2007-2010. During 2010-2014, 11,396 cervicovaginal samples were collected from 13,545 18.5-year-old attendees. HPV typing was performed by a high-throughput PCR. VE was calculated for HPV vaccinated women and HE for non-HPV-vaccinated women, using the HBV vaccinated, for HE all non-HPV vaccinated, Arm C women as controls. PE was calculated as coverage rate-weighted mean of VE + HE. HPV16/18/45 and 31/33/35 VEs varied between 86-94% and 30-66%, respectively. Only the gender-neutral vaccination provided significant HEs against HPV18 (61%) and HPV31 (72%) in the 1995 birth cohort-increased HEs against HPV33 (39%) and HPV35 (42%) were also observed. Due to the increased HEs, PEs for HPV16/18/45 and HPV31/33/35 were comparable in the gender-neutral arm 1995 birth cohort. High vaccine efficacy against HPV16/18/45 and, gender-neutral vaccination-enforced, herd effect against HPV18/31/33/35 by the bivalent vaccine rapidly provides comparable overall protective effectiveness against six oncogenic HPV types: 16/18/31/33/35/45., (© 2018 UICC.)
- Published
- 2018
- Full Text
- View/download PDF
5. Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females-Post-hoc analysis of a community-randomized clinical trial (II).
- Author
-
Gray P, Palmroth J, Luostarinen T, Apter D, Dubin G, Garnett G, Eriksson T, Natunen K, Merikukka M, Pimenoff V, Söderlund-Strand A, Vänskä S, Paavonen J, Pukkala E, Dillner J, and Lehtinen M
- Subjects
- Adolescent, Female, Humans, Male, Papillomavirus Infections epidemiology, Prevalence, Vaccination, Papillomavirus Infections prevention & control, Papillomavirus Infections virology, Papillomavirus Vaccines
- Abstract
Efficacy of human papillomavirus (HPV) vaccines promises to control HPV infections. However, HPV vaccination programs may lay bare an ecological niche for non-vaccine HPV types. We evaluated type-replacement by HPV type and vaccination strategy in a community-randomized trial executed in HPV vaccination naïve population. Thirty-three communities were randomized to gender-neutral vaccination with AS04-adjuvanted HPV16/18 vaccine (Arm A), HPV vaccination of girls and hepatitis B-virus (HBV) vaccination of boys (Arm B) and gender-neutral HBV vaccination (Arm C). Resident 1992-95 born boys (40,852) and girls (39,420) were invited. 11,662 boys and 20,513 girls were vaccinated with 20-30% and 45-48% coverage, respectively. HPV typing of 11,396 cervicovaginal samples was performed by high throughput PCR. Prevalence ratios (PR) between arms and ranked order of HPV types and odds ratio (OR) for having multiple HPV types in HPV16 or 18/45 positive individuals were calculated. The ranked order of HPV types did not significantly differ between arms or birth cohorts. For the non-HPV vaccinated 1992-1993 birth cohorts increased PR, between the gender-neutral intervention versus control arms for HPV39 (PR
A 1.84, 95% CI 1.12-3.02) and HPV51 (PRA 1.56, 95% CI 1.11-2.19) were observed. In the gender-neutral arm, increased clustering between HPV39 and the vaccine-covered HPV types 16 or 18/45 (ORA16 = 5.1, ORA18/45 = 11.4) was observed in the non-HPV vaccinated 1994-1995 birth cohorts. Comparable clustering was seen between HPV51 and HPV16 or HPV18/45 (ORB16 = 4.7, ORB18/45 = 4.3), in the girls-only arm. In conclusion, definitively consistent postvaccination patterns of HPV type-replacement were not observed. Future occurrence of HPV39 and HPV51 warrant investigation., (© 2018 UICC.)- Published
- 2018
- Full Text
- View/download PDF
6. Vaccination protects against invasive HPV-associated cancers.
- Author
-
Luostarinen T, Apter D, Dillner J, Eriksson T, Harjula K, Natunen K, Paavonen J, Pukkala E, and Lehtinen M
- Subjects
- Adolescent, Adult, Clinical Trials, Phase III as Topic, Female, Finland epidemiology, Human papillomavirus 11 immunology, Human papillomavirus 16 immunology, Human papillomavirus 18 immunology, Humans, Incidence, Neoplasms prevention & control, Papillomavirus Infections prevention & control, Randomized Controlled Trials as Topic, Uterine Cervical Neoplasms epidemiology, Uterine Cervical Neoplasms prevention & control, Uterine Cervical Neoplasms virology, Young Adult, Uterine Cervical Dysplasia epidemiology, Uterine Cervical Dysplasia prevention & control, Uterine Cervical Dysplasia virology, Neoplasms epidemiology, Neoplasms virology, Papillomavirus Infections epidemiology, Papillomavirus Vaccines therapeutic use
- Published
- 2018
- Full Text
- View/download PDF
7. Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I).
- Author
-
Lehtinen M, Söderlund-Strand A, Vänskä S, Luostarinen T, Eriksson T, Natunen K, Apter D, Baussano I, Harjula K, Hokkanen M, Kuortti M, Palmroth J, Petäjä T, Pukkala E, Rekonen S, Siitari-Mattila M, Surcel HM, Tuomivaara L, Paavonen J, Dillner J, Dubin G, and Garnett G
- Subjects
- Adolescent, Adult, Female, Finland epidemiology, Humans, Incidence, Male, Papillomavirus Infections epidemiology, Papillomavirus Infections virology, Prognosis, Uterine Cervical Neoplasms epidemiology, Uterine Cervical Neoplasms virology, Vaccination, Young Adult, Papillomaviridae pathogenicity, Papillomavirus Infections prevention & control, Papillomavirus Vaccines therapeutic use, Uterine Cervical Neoplasms prevention & control
- Abstract
Human papillomavirus (HPV) vaccine is efficacious but the real-life effectiveness of gender-neutral and girls-only vaccination strategies is unknown. We report a community-randomized trial on the protective effectiveness [(PE) = vaccine efficacy (VE) + herd effect (HE)] of the two strategies among females in virtually HPV vaccination naïve population. We randomized 33 Finnish communities into Arm A) gender-neutral vaccination with AS04-adjuvanted HPV16/18 vaccine (11 communities), Arm B) HPV vaccination of girls and hepatitis B-virus (HBV) vaccination of boys (11 communities) or Arm C) gender-neutral HBV vaccination (11 communities). All resident 39,420 females and 40,852 males born 1992-95 were invited in 2007-09. Virtually all (99%) 12- to 15-year-old participating males (11,662) and females (20,513) received three doses resulting in uniform 20-30% male and 50% female vaccination coverage by birth cohort. Four years later (2010-14) 11,396 cervicovaginal samples obtained from 18.5 year-old women were tested for HPV DNA, and prevalence of cervical HPV infections by trial arm and birth cohort was the main outcome measure. VEs against HPV16/18 varied between 89.2% and 95.2% across birth cohorts in arms A and B. The VEs against non-vaccine types consistent with cross-protection were highest in those born 1994-95 for HPV45 (VE
A 82.8%; VEB 86.1%) and for HPV31 (VEA 77.6%, VEB 84.6%). The HEs in the non HPV-vaccinated were statistically significant in those born 1994-95 for HPV18 (HEA 51.0%; 95% CI 8.3-73.8, HEB 47.2%; 6.5-70.2) and for HPV31/33 in arm A (HEA 53.7%; 22.1-72.5). For HPV16 and 45 no significant herd effects were detected. PE estimates against HPV16/18 were similar by both strategies (PEA 58.1%; 45.1-69.4; PEB 55.7%; 42.9-66.6). PE estimates against HPV31/33 were higher by the gender-neutral vaccination (PEA 60.5%; 43.6-73.4; PEB 44.5%; 24.9-60.6). In conclusion, while gender-neutral strategy enhanced the effectiveness of HPV vaccination for cross-protected HPV types with low to moderate coverage, high coverage in males appears to be key to providing a substantial public health benefit also to unvaccinated females. Trial registration www.clinicaltrials.gov.com NCT000534638., (© 2017 UICC.)- Published
- 2018
- Full Text
- View/download PDF
8. Improving cervical cancer screening attendance in Finland.
- Author
-
Virtanen A, Anttila A, Luostarinen T, Malila N, and Nieminen P
- Subjects
- Adult, Female, Finland, Humans, Middle Aged, Socioeconomic Factors, Early Detection of Cancer statistics & numerical data, Uterine Cervical Neoplasms diagnosis
- Abstract
High attendance is essential to cervical cancer screening results. Attendance in the Finnish program is currently at 70%, but extensive opportunistic screening occurs beside the organized. A shift from opportunistic to organized screening is imperative to optimize the costs and impact of screening and minimize potential harms. We evaluated the effect of reminder letters (1st reminder) and self-sampling test (2nd reminder) on program attendance. The study population consisted of 31,053 screening invitees in 31 Finnish municipalities. 8,284 non-attendees after one invitation received a reminder letter and 4,536 further non-attendees were offered a self-sampling option. Socioeconomic factors related to participation were clarified by combining screening data to data from Statistics Finland. Reminder letters increased participation from 72.6% (95% CI 72.1, 73.1) to 79.2% (95% CI 78.8, 79.7) and self-sampling further to 82.2% (95% CI 81.8, 82.7). Reminder letters with scheduled appointments resulted in higher increase than open invitations (10 vs. 6%). Screening of original non-attendees increased the yield of CIN3+ lesions by 24%. Non-attendance was associated with young age, immigrant background, lower education level and having never been married. We showed that a total attendance of well over 80% can be achieved within an organized program when the invitational protocol is carefully arranged., (© 2014 UICC.)
- Published
- 2015
- Full Text
- View/download PDF
9. Prospective study of genital human papillomaviruses and nonmelanoma skin cancer.
- Author
-
Andersson K, Luostarinen T, Strand AS, Langseth H, Gislefoss RE, Forslund O, Pawlita M, Waterboer T, and Dillner J
- Subjects
- Aged, Antibodies, Viral blood, DNA, Viral analysis, Female, Humans, Male, Middle Aged, Prospective Studies, Registries, Reproductive Tract Infections virology, Carcinoma, Basal Cell virology, Carcinoma, Squamous Cell virology, Human papillomavirus 16 immunology, Human papillomavirus 18 immunology, Papillomavirus Infections virology, Skin Neoplasms virology
- Abstract
Genital high-risk human papillomaviruses (HPVs) cause cervical cancer and are also found in a small proportion of nonmelanoma skin cancers (NMSCs). We used cancer registry linkages to follow the 856,000 serum donors included in the Southern Sweden Microbiology Biobank or the Janus Biobank in Norway, for incident skin cancers occurring up to 30 years after serum donation. Serum samples taken before diagnosis of squamous cell carcinoma (SCC) (N = 633), basal cell carcinoma (BCC) (N = 1990) or other NMSC (N = 153) and matched samples from control donors were tested for antibodies to the genital HPV types 16 and 18. Both HPV 16 and 18 were associated with increased risk for SCC [odds ratio (OR) 1.6, 95% confidence interval (CI) 1.1-2.6 and OR 1.7, 95% CI 1.1-2.5, respectively] and other NMSC (OR 2.3, 95% CI 1.0-5.2 and OR 3.5, 95% CI 1.4-8.7, respectively), but not for BCC. Tumor blocks from HPV16 or 18 seropositive cases were tested with real-time polymerase chain reaction for presence of HPV16 or 18 DNA. No HPV18 DNA was found and only four of 79 SCC cases (two of which were from the perineum/perianal area), one of 221 BCC cases and zero of five cases with other NMSC contained HPV16 DNA. In conclusion, we found prospective evidence that HPV16 and 18 antibodies associate with SCC and other NMSC risk, but not with BCC risk. As only a small proportion of seropositive subjects had evidence of the corresponding HPV DNA in the tumor, most of this excess risk is likely to be due to confounders associated with genital HPV infection., (Copyright © 2013 UICC.)
- Published
- 2013
- Full Text
- View/download PDF
10. Order of HPV/Chlamydia infections and cervical high-grade precancer risk: a case-cohort study.
- Author
-
Luostarinen T, Namujju PB, Merikukka M, Dillner J, Hakulinen T, Koskela P, Paavonen J, Surcel HM, and Lehtinen M
- Subjects
- Antibodies, Bacterial blood, Antibodies, Viral blood, Chlamydia Infections immunology, Chlamydia trachomatis immunology, Cohort Studies, Female, Finland epidemiology, Humans, Papillomaviridae immunology, Papillomavirus Infections immunology, Risk Factors, Chlamydia Infections epidemiology, Papillomavirus Infections epidemiology, Precancerous Conditions epidemiology, Uterine Cervical Neoplasms epidemiology
- Abstract
Interactions of carcinogenic human papillomaviruses (most notably HPV types 16/18/31/33/45), and HPV6 or Chlamydia trachomatis are not well understood. We have used seroconversions to study effects the order of these infections has on the risk of high-grade cervical precancer. In a cohort of 94,349 Finnish women with paired sera from consecutive pregnancies within an average of 2.4 years, 490 were diagnosed with cervical CIN3/AIS. Serum antibodies to HPV6/16/18/31/33/45 and C. trachomatis were measured in paired sera of the cases and a subcohort of 2,796 women with a minimum of two pregnancies. HPV16-adjusted rate ratios (RR) and confidence intervals were estimated by stratified Cox model. Compared to dual seropositivity already at the first serum sampling, RRs related to HPV6 seropositivity before and after HPV31 seroconversion were 0.4 (95% CI 0.0, 4.4) and 10 (95% CI 1.8, 57). Furthermore, RR related to seroconversions of both HPV18/45 and C.trachomatis between the consecutive pregnancies was 28 (95% CI 4.3, 190). Virtually concomitant HPV18/45 and C.trachomatis infections are associated with very high CIN3 risk., (© 2013 UICC.)
- Published
- 2013
- Full Text
- View/download PDF
11. Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: Cancer registry-based follow-up.
- Author
-
Rana MM, Huhtala H, Apter D, Eriksson T, Luostarinen T, Natunen K, Paavonen J, Pukkala E, and Lehtinen M
- Subjects
- Adolescent, Adult, Female, Finland, Follow-Up Studies, Humans, Incidence, Population Surveillance, Registries, Uterine Cervical Neoplasms epidemiology, Uterine Cervical Neoplasms pathology, Young Adult, Cancer Vaccines immunology, Papillomaviridae immunology, Papillomavirus Vaccines immunology, Uterine Cervical Neoplasms prevention & control, Vaccination
- Abstract
Phase III clinical trials of human papilloma virus (HPV) vaccination have shown ≥95% efficacy against HPV16/18 associated cervical intraepithelial neoplasia (CIN) Grade 2/3. Long-term surveillance is, however, needed to determine the overall vaccine efficacy (VE) against CIN3 and invasive cervical carcinoma (ICC). During population-based recruitment between September 2002 and March 2003, 1,749 16- to 17-year old Finns participated in a multi-national randomized Phase III HPV6/11/16/18 vaccine (FUTURE II) trial for the determination of VE against HPV16/18 positive CIN2/3. The passive follow-up started at the country-wide, population-based Finnish Cancer Registry (FCR) six months after the active follow-up and voluntary cross-vaccination in April 2007. A cluster randomized, population-based reference cohort of 15,744 unvaccinated, originally 18-19 year old Finns was established in two phases in 2003 and 2005 after the FUTURE II recruitment. We linked these cohorts with the FCR in 2007-2011 (HPV vaccine and placebo cohorts) and 2006-2010 and 2008-2012 (unvaccinated reference cohorts 1 and 2) to compare their incidences of CIN3 and ICC. The four years passive follow-up resulted in 3,464, 3,444 and 62,876 person years for the HPV6/11/16/18, original placebo and reference cohorts, after excluding cases discovered during the clinical follow-up and individuals not at risk. The numbers of CIN3 and ICC cases identified were 0 and 0, 3 and 0, 59 and 3 for the HPV6/11/16/18, placebo and the unvaccinated reference cohorts. The corresponding CIN3 incidence rates were 0/100,000 (95% confidence interval 0.0-106.5), 87.1/100,000 (95% CI 17.9-254.5) and 93.8/100,000 (95% CI 71.4-121), respectively. Long-term surveillance up to 8 years (and longer) post vaccination of the HPV6/11/16/18 vaccine and placebo cohorts, and the unvaccinated reference cohort (not exposed to interventions) for the most stringent efficacy end-points by passive cancer registry-based follow-up is feasible., (Copyright © 2012 UICC.)
- Published
- 2013
- Full Text
- View/download PDF
12. Mortality audit of the Finnish cervical cancer screening program.
- Author
-
Lönnberg S, Nieminen P, Luostarinen T, and Anttila A
- Subjects
- Adenocarcinoma pathology, Adult, Age Factors, Aged, Aged, 80 and over, Carcinoma, Squamous Cell pathology, Case-Control Studies, Cohort Studies, Female, Finland epidemiology, Follow-Up Studies, Humans, Middle Aged, Neoplasm Staging, Prognosis, Risk Factors, Survival Rate, Uterine Cervical Neoplasms, Adenocarcinoma mortality, Carcinoma, Squamous Cell mortality, Early Detection of Cancer mortality, Medical Audit
- Abstract
Incidence-based evaluations of cervical cancer screening programs have suggested age-specific impacts and there is uncertainty regarding the effectiveness of screening outside the ages of 30-60 years. We audited the screening histories of cervical cancer deaths and conducted a case-control evaluation of the effectiveness of organized screening in different ages with mortality as outcome. We included all 506 cervical cancer deaths in Finland in 2000-2009 due to cancers diagnosed in 1990 or later, and 3,036 controls matched by age at diagnosis to the cases. Squamous cell carcinoma constituted 59% of the cases, adenocarcinomas 29%, and the remaining 12% were other specified and unspecified cervical malignancies. Most deaths (54%) were due to cancers diagnosed more than 5 years after last screening invitation, 24% were diagnosed among nonattenders and only 14% of deaths occurred among women who had attended invitational screening. The risk reduction associated with attending a single program screen at an age below 40 was nonsignificant (OR 0.70; 95% CI 0.33-1.48), while clear risk reductions were observed after screening at the age of 40-54 (OR 0.33; CI 0.20-0.56) and 55-69 (OR 0.29; CI 0.16-0.54). This study also provides some indication of a long-lasting additional effect of screening at the age of 65. Possible avenues for improving the effectiveness of the Finnish screening program include efforts to increase attendance and an extension of the target ages to include 65-to 69-year-old women. The potential benefit of increasing the sensitivity of the screening test or shortening the screening interval is smaller., (Copyright © 2012 UICC.)
- Published
- 2013
- Full Text
- View/download PDF
13. Self-sampling versus reminder letter: effects on cervical cancer screening attendance and coverage in Finland.
- Author
-
Virtanen A, Anttila A, Luostarinen T, and Nieminen P
- Subjects
- Adult, Aged, Female, Finland, Humans, Middle Aged, Prognosis, Uterine Cervical Neoplasms prevention & control, Early Detection of Cancer, Papanicolaou Test, Patient Acceptance of Health Care, Patient Compliance, Reminder Systems, Self Care, Uterine Cervical Neoplasms diagnosis, Vaginal Smears statistics & numerical data
- Abstract
Optimizing attendance and coverage of organized screening is needed to reduce cervical cancer incidence to previous lower levels. In our study, all nonparticipants in organized cervical cancer screening in 2008 in Espoo, Finland were randomized to receive a self-sampling kit (1,130 women) or a reminder letter (3,030 women). Effects on screening coverage were assessed according to the self-reported previous Pap smear history of the participants. Participation rate in the self-sampling arm, 29.8%, was significantly higher than in the reminder letter arm, 26.2% (adjusted relative risk for participation 1.13). Total participation in Espoo in 2008 rose significantly after the two interventions from 64.0 to 75.4%. In both arms, ∼ 20% of the participants after second intervention could be considered under screened (previous Pap smear ≥ 5 years ago) and thus increased screening coverage. Respectively, for 70-75%, the second intervention only provided overscreening. Participation was lowest among young age groups and immigrants, after primary invitation and after interventions. Our study shows that a second intervention for nonattendees after the first invitation is needed to optimize the attendance rates. Self-sampling might be slightly more successful in this, but the effects on screening coverage were similar in both groups., (Copyright © 2010 UICC.)
- Published
- 2011
- Full Text
- View/download PDF
14. A randomised public-health trial on automation-assisted screening for cervical cancer in Finland: performance with 470,000 invitations.
- Author
-
Nieminen P, Kotaniemi L, Hakama M, Tarkkanen J, Martikainen J, Toivonen T, Ikkala J, Luostarinen T, and Anttila A
- Subjects
- Adult, Automation, Female, Finland epidemiology, Humans, Incidence, Middle Aged, Neoplasm Invasiveness pathology, Papanicolaou Test, Public Health, Sensitivity and Specificity, Uterine Cervical Dysplasia epidemiology, Uterine Cervical Neoplasms epidemiology, Vaginal Smears, Mass Screening, Uterine Cervical Dysplasia diagnosis, Uterine Cervical Neoplasms diagnosis
- Abstract
Our objective was to evaluate automation-assisted screening, in comparison to the conventional method, in a routine population-based cervical cancer-screening programme. Our study is based on an individually randomised design involving approximately 160,000 invitees and 110,000 attendees every year. From 1999 to 2001, 471,297 women were invited to attend and 330,445 smears were screened (attendance rate 70.1%), of which 220,254 were tested conventionally and 110,191 were tested using the automation-assisted method. Cytologic Papanicolaou group II findings were reported slightly more often (RR = 1.04) in the automation-assisted method than in the conventional screening arm. There were 1,291 cases of histologically confirmed dysplasia or carcinoma (0.4% of the screened), one-third of which were severe dysplasia or a more severe finding (CIN3+). The detection rates of histologically verified findings were similar between the 2 screening arms. In Finland, the screening programme has been effective. As the detection rates, particularly of CIN3+, were similar between the screening arms, we will continue the automation-assisted method in the routine screening programme. Further follow-up for interval cancer incidence is required, however, to measure if the effect of screening is the same between the arms. A similar evaluation design is feasible to any other major or competing modification of the screening test or other element in the programme., (Copyright 2005 Wiley-Liss, Inc)
- Published
- 2005
- Full Text
- View/download PDF
15. Maternal human polyomavirus infection and risk of neuroblastoma in the child.
- Author
-
Stolt A, Kjellin M, Sasnauskas K, Luostarinen T, Koskela P, Lehtinen M, and Dillner J
- Subjects
- Adolescent, Adult, Antibodies, Viral blood, BK Virus genetics, BK Virus immunology, Case-Control Studies, Child, Cohort Studies, DNA, Viral genetics, Female, Humans, Immunoglobulin G blood, Immunoglobulin G immunology, Immunoglobulin M blood, Immunoglobulin M immunology, JC Virus genetics, JC Virus immunology, Polymerase Chain Reaction, Polyomavirus genetics, Pregnancy, Risk Factors, Seroepidemiologic Studies, Transformation, Genetic, Tumor Cells, Cultured, Neuroblastoma virology, Polyomavirus Infections virology, Pregnancy Complications, Infectious virology
- Abstract
To investigate if polyomavirus infection during pregnancy is linked to development of neuroblastoma in the child, serum samples of 115 index mothers from the pregnancy where the child eventually developed neuroblastoma were identified and matched with serum samples from 8 control mothers per index mother. The samples were tested for specific IgG and IgM antibodies to BK and JC virus using enzyme immunoassays based on purified yeast-expressed virus-like particles (VLPs). The serum samples as well as 10 neuroblastoma cell lines were also analyzed using Real Time (TaqMan) PCR for detection and quantification of BK virus DNA. The BK virus IgG seroprevalence was similar among index mothers (80%) and control mothers (83%) [OR 0.8; 95% confidence interval (95% CI): 0.5-1.3]. BK virus IgM was also not associated with neuroblastoma risk (OR was OR = 0.6; 95% with CI, 0.2-1.9). Also JC virus had no association, neither for IgG (OR = 0.9; 95% CI, 0.6-1.4) nor for IgM (OR = 0.9; 95% CI, 0.4-1.9). All serum samples and all neuroblastoma cell lines were negative for BKV DNA. In summary, a comprehensive cohort using both serology and polyomavirus DNA detection found no evidence for association between BKV or JCV polyomaviruses and neuroblastoma.
- Published
- 2005
- Full Text
- View/download PDF
16. Survival of in situ carcinoma of cervix uteri: a 50-year follow-up in Finland.
- Author
-
Hakama M, Luostarinen T, and Hakulinen T
- Subjects
- Adult, Age Distribution, Age of Onset, Aged, Aged, 80 and over, Female, Finland epidemiology, Follow-Up Studies, Humans, Middle Aged, Registries, Survival Rate, Uterine Cervical Neoplasms diagnosis, Uterine Cervical Dysplasia diagnosis, Uterine Cervical Neoplasms mortality, Uterine Cervical Dysplasia mortality
- Abstract
Preinvasive lesions of cervix uteri are regarded a curable disease despite some progression to invasive cancer. The ultimate outcome is not known. We estimated the 45-year survival of 12,655 patients with carcinoma in situ lesions diagnosed in 1953-2000 and reported to the Finnish Cancer Registry. Up to 30 years of follow-up there was about 1% decrease in cumulative relative survival per 5 years of follow-up. After that the excess mortality increased and the survival at 45 years was 84%. The 15-year survival was 100% in the patients under 30 at diagnosis and became the poorer the older the patient. Survival was 89% in the patients 60-74 at diagnosis. Women with carcinoma in situ are at substantial increased risk of death (>10%) only at high ages and independent of age at diagnosis., ((c) 2004 Wiley-Liss, Inc.)
- Published
- 2004
- Full Text
- View/download PDF
17. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study.
- Author
-
Stattin P, Lumme S, Tenkanen L, Alfthan H, Jellum E, Hallmans G, Thoresen S, Hakulinen T, Luostarinen T, Lehtinen M, Dillner J, Stenman UH, and Hakama M
- Subjects
- Adult, Aged, Androgens blood, Biomarkers blood, Case-Control Studies, Cohort Studies, Finland epidemiology, Humans, Male, Middle Aged, Norway epidemiology, Prospective Studies, Prostate, Risk Factors, Sex Hormone-Binding Globulin metabolism, Sweden epidemiology, Prostatic Neoplasms blood, Prostatic Neoplasms epidemiology, Testosterone blood
- Abstract
Androgens stimulate prostate cancer in vitro and in vivo. However, evidence from epidemiologic studies of an association between circulating levels of androgens and prostate cancer risk has been inconsistent. We investigated the association of serum levels of testosterone, the principal androgen in circulation, and sex hormone-binding globulin (SHBG) with risk in a case-control study nested in cohorts in Finland, Norway and Sweden of 708 men who were diagnosed with prostate cancer after blood collection and among 2,242 men who were not. In conditional logistic regression analyses, modest but significant decreases in risk were seen for increasing levels of total testosterone down to odds ratio for top vs. bottom quintile of 0.80 (95% CI = 0.59-1.06; p(trend) = 0.05); for SHBG, the corresponding odds ratio was 0.76 (95% CI = 0.57-1.01; p(trend) = 0.07). For free testosterone, calculated from total testosterone and SHBG, a bell-shaped risk pattern was seen with a decrease in odds ratio for top vs. bottom quintile of 0.82 (95% CI = 0.60-1.14; p(trend) = 0.44). No support was found for the hypothesis that high levels of circulating androgens within a physiologic range stimulate development and growth of prostate cancer., (Copyright 2003 Wiley-Liss, Inc.)
- Published
- 2004
- Full Text
- View/download PDF
18. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries.
- Author
-
Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G, Stattin P, Harvei S, Hakulinen T, Luostarinen T, Dillner J, Lehtinen M, and Hakama M
- Subjects
- Adult, Case-Control Studies, Finland, Humans, Longitudinal Studies, Male, Middle Aged, Norway, Risk, Sweden, Vitamin D Deficiency complications, Calcifediol blood, Prostatic Neoplasms blood
- Abstract
Vitamin D inhibits the development and growth of prostate cancer cells. Epidemiologic results on serum vitamin D levels and prostate cancer risk have, however, been inconsistent. We conducted a longitudinal nested case-control study on Nordic men (Norway, Finland and Sweden) using serum banks of 200,000 samples. We studied serum 25(OH)-vitamin D levels of 622 prostate cancer cases and 1,451 matched controls and found that both low (=19 nmol/l) and high (>/=80 nmol/l) 25(OH)-vitamin D serum concentrations are associated with higher prostate cancer risk. The normal average serum concentration of 25(OH)-vitamin D (40-60 nmol/l) comprises the lowest risk of prostate cancer. The U-shaped risk of prostate cancer might be due to similar 1,25-dihydroxyvitamin D(3) availability within the prostate: low vitamin D serum concentration apparently leads to a low tissue concentration and to weakened mitotic control of target cells, whereas a high vitamin D level might lead to vitamin D resistance through increased inactivation by enhanced expression of 24-hydroxylase. It is recommended that vitamin D deficiency be supplemented, but too high vitamin D serum level might also enhance cancer development., (Copyright 2003 Wiley-Liss, Inc.)
- Published
- 2004
- Full Text
- View/download PDF
19. A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma.
- Author
-
Wallin KL, Wiklund F, Luostarinen T, Angström T, Anttila T, Bergman F, Hallmans G, Ikäheimo I, Koskela P, Lehtinen M, Stendahl U, Paavonen J, and Dillner J
- Subjects
- Adult, Aged, Biopsy, Chlamydia Infections epidemiology, DNA, Bacterial analysis, DNA, Viral analysis, Female, Humans, Middle Aged, Papanicolaou Test, Papillomaviridae genetics, Polymerase Chain Reaction, Prospective Studies, Risk, Sweden epidemiology, Uterine Cervical Neoplasms diagnosis, Uterine Cervical Neoplasms virology, Vaginal Smears, Chlamydia Infections diagnosis, Chlamydia trachomatis genetics, Uterine Cervical Neoplasms microbiology
- Abstract
Persistent human papillomavirus (HPV) infection is an established cause of cervical cancer, but the role of other sexually transmitted agents, most notably Chlamydia trachomatis, has not been well defined. The women participating in the population-based cervical cancer screening program in Västerbotten county of Northern Sweden were followed up for up to 26 years to identify 118 women who developed cervical cancer after having had a normal Pap smear (on average 5.6 years later; range 0.5 months-26 years). As controls, we selected another 118 women who were matched by birth cohort, time-point of sampling of the baseline normal smear and who had a normal smear at the time when the corresponding case was diagnosed with cancer. The Pap smears and cervical cancer biopsies were analyzed by PCR for C. trachomatis DNA and for HPV DNA. At baseline, C. trachomatis DNA was present in 8% of cases but not among any one of the controls. The relative risk for cervical cancer associated with past C. trachomatis infection, adjusted for concomitant HPV DNA positivity, was 17.1 (95% CI 2.6-infinity). The presence of C. trachomatis and of HPV were not interrelated. Whereas C. trachomatis was primarily found in specimens taken many years before cancer diagnosis, HPV DNA was associated with a short lag time before cancer diagnosis. Whereas most women who were HPV DNA-positive in the prediagnostic smear were also positive for the same virus in the cervical cancer biopsy, none of the women were positive for C. trachomatis in both the prediagnostic smear and in the subsequent cervical cancer. In conclusion, a prior cervical C. trachomatis infection was associated with an increased risk for development of invasive cervical cancer., (Copyright 2002 Wiley-Liss, Inc.)
- Published
- 2002
- Full Text
- View/download PDF
20. Circulating enterolactone and prostate cancer risk: a Nordic nested case-control study.
- Author
-
Stattin P, Adlercreutz H, Tenkanen L, Jellum E, Lumme S, Hallmans G, Harvei S, Teppo L, Stumpf K, Luostarinen T, Lehtinen M, Dillner J, and Hakama M
- Subjects
- Case-Control Studies, Cohort Studies, Estrogens blood, Finland epidemiology, Fluoroimmunoassay, Humans, Male, Middle Aged, Norway epidemiology, Prospective Studies, Prostatic Neoplasms blood, Risk Factors, Sweden epidemiology, 4-Butyrolactone analogs & derivatives, 4-Butyrolactone blood, Lignans blood, Prostatic Neoplasms epidemiology
- Abstract
Enterolactone, a phytoestrogen belonging to the class of lignans, is produced by the intestinal microflora from precursors in plant foods and has been implicated in protection against cancer. We study the effect of enterolactone on the risk of a subsequent diagnosis of prostate cancer. We conducted a longitudinal, nested case-control study by linkage of 3 biobanks to the cancer registries in Finland, Norway and Sweden, respectively. Enterolactone concentrations were measured by time-resolved fluoroimmunoassay in serum from 794 men who had a diagnosis of prostate cancer at a mean follow-up time of 14.2 years after blood collection and among 2,550 control men matched within each cohort for age (+/-2 years), date of blood collection (+/-2 months) and county. The median enterolactone concentrations did not differ between case and control subjects in the full study group (8.4 nmol/L [25th-75th percentile = 4.5-15.0] vs. 8.5 nmol/L [25th-75th percentile = 4.3-15.9]), nor in the national groups. Odds ratios of prostate cancer risk estimated by conditional logistic regression for increasing concentrations of enterolactone in quartiles in the full study group were 1.00 (referent), 1.21 (95% confidence interval [CI] = 0.96-1.52), 1.16 (95% CI = 0.91-1.47) and 1.08 (95% CI = 0.83-1.39). The OR estimate for the highest vs. the lowest quartile of enterolactone in separate analyses of the Norwegian, Finnish and Swedish cohort was 1.21 (95% CI = 0.91-1.60), 1.02 (95% CI = 0.59-1.76) and 0.87 (95% CI = 0.45-1.67), respectively. No support for the hypothesis that high circulating enterolactone is protective against prostate cancer was found., (Copyright 2002 Wiley-Liss, Inc.)
- Published
- 2002
- Full Text
- View/download PDF
21. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer.
- Author
-
Koskela P, Anttila T, Bjørge T, Brunsvig A, Dillner J, Hakama M, Hakulinen T, Jellum E, Lehtinen M, Lenner P, Luostarinen T, Pukkala E, Saikku P, Thoresen S, Youngman L, and Paavonen J
- Subjects
- Adenocarcinoma blood, Adenocarcinoma microbiology, Antibodies, Bacterial blood, Carcinoma, Squamous Cell blood, Carcinoma, Squamous Cell microbiology, Case-Control Studies, Chlamydia Infections blood, Chlamydia Infections complications, Chlamydia Infections microbiology, Cohort Studies, Female, Finland, Humans, Neoplasm Invasiveness, Norway, Odds Ratio, Prospective Studies, Risk Factors, Seroepidemiologic Studies, Smoking epidemiology, Sweden, Uterine Cervical Neoplasms blood, Adenocarcinoma epidemiology, Carcinoma, Squamous Cell epidemiology, Chlamydia Infections epidemiology, Chlamydia trachomatis immunology, Uterine Cervical Neoplasms epidemiology, Uterine Cervical Neoplasms microbiology
- Abstract
Cervical carcinoma is a sexually transmitted disease most strongly linked with human-papillomavirus (HPV) infection. We conducted a prospective sero-epidemiologic study to evaluate the role of Chlamydia trachomatis infection in the development of cervical carcinoma, with invasive cancer as an end point. A nested case-control study within a cohort of 530000 Nordic women was performed. Linking data files of 3 Nordic serum banks and the cancer registries of Finland, Norway and Sweden identified 182 women with invasive cervical carcinoma diagnosed during a mean follow-up of 5 years after serum sampling. The serum samples of the cases and matched cancer-free controls were analyzed for IgG antibodies to C. trachomatis, C. pneumoniae (a control microbe) and HPV types 16, 18 and 33, as well as for serum cotinine (an indicator of tobacco smoking). Serum antibodies to C. trachomatis were associated with an increased risk for cervical squamous-cell carcinoma (HPV- and smoking-adjusted OR, 2.2; 95% CI, 1.3-3.5). The association remained also after adjustment for smoking both in HPV16-seronegative and -seropositive cases (OR, 3.0; 95% CI, 1.8-5.1; OR, 2.3, 95% CI, 0. 8-7.0 respectively). No such association was found for C. pneumoniae. Our prospective study provides sero-epidemiologic evidence that infection with C. trachomatis confers an increased risk for subsequent development of invasive squamous-cell carcinoma of the uterine cervix., (Copyright 2000 Wiley-Liss, Inc.)
- Published
- 2000
- Full Text
- View/download PDF
22. No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11.
- Author
-
Luostarinen T, af Geijersstam V, Bjørge T, Eklund C, Hakama M, Hakulinen T, Jellum E, Koskela P, Paavonen J, Pukkala E, Schiller JT, Thoresen S, Youngman LD, Dillner J, and Lehtinen M
- Subjects
- Adult, Antibodies, Viral immunology, Blood Donors, Chlamydia Infections epidemiology, Cohort Studies, Comorbidity, Cross Reactions, Female, Finland epidemiology, Humans, Norway epidemiology, Papillomaviridae classification, Papillomaviridae immunology, Papillomaviridae isolation & purification, Papillomavirus Infections virology, Pregnancy, Pregnancy Complications, Infectious epidemiology, Pregnancy Complications, Infectious virology, Prospective Studies, Seroepidemiologic Studies, Sexual Behavior statistics & numerical data, Smoking epidemiology, Species Specificity, Sweden epidemiology, Tumor Virus Infections virology, Uterine Cervical Neoplasms virology, Antibodies, Viral blood, Papillomaviridae pathogenicity, Papillomavirus Infections epidemiology, Tumor Virus Infections epidemiology, Uterine Cervical Neoplasms epidemiology
- Abstract
Human papillomavirus (HPV) types 16 and 18 are the major risk factors for cervical carcinoma, whereas HPV types 6 and 11 cause benign genital lesions. We wanted to study the joint effect of simultaneous infections with the oncogenic and non-oncogenic HPV types on risk of subsequent development of cervical carcinoma. A cohort of 530,000 women who had donated blood samples to Nordic serum banks between 1973 and 1994 was followed up by linkage to national cancer registries. We identified 182 prospective cases with invasive cervical carcinoma and selected 538 matched controls at random. HPV 6, 11, 16, 18 and 33 seropositivity was used as a marker for the different HPV infections, and seropositivity for Chlamydia trachomatis and cotinine were used as markers for risk-taking sexual behavior and smoking respectively. The adjusted odds ratio (OR) of cervical squamous-cell carcinoma (SCC) was 2.2 for HPV6/11 among HPV16 seronegatives and 5.5 for HPV16 among HPV6/11 seronegatives. Assuming multiplicative joint effect, the expected OR for seropositivity to both HPV6/11 and HPV16 would have been 12, but the observed OR was 1.0. The antagonistic interaction was statistically significant (p = 0.001) and present also under deterministic considerations of possible misclassification bias. Antagonistic interactions were also detected for combinations of HPV16 and HPV18 and of HPV16 and HPV33. The results are in line with the concept that HPV-specific immunity protects against SCC and support primary prevention of SCC by vaccination against the HPVs.
- Published
- 1999
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.